Despite hitting its primary endpoints, the Novo Nordisk REDEFINE 1 Phase III trial saw patients achieving a weight loss of 22.7% after 68 weeks on CariSema. Credit: Getty Images / Bloomberg Danish ...
RAG-17 is tailored for the SOD1 gene suppression in individuals with ALS having pathogenic mutations. Credit: CC7/Shutterstock. Ractigen Therapeutics has dosed the first subject in the randomised ...